Equities research analysts expect Baxter International Inc. (NYSE:BAX) to announce earnings per share of $0.59 for the current quarter, Zacks Investment Research reports. Six analysts have issued estimates for Baxter International’s earnings, with the lowest EPS estimate coming in at $0.57 and the highest estimate coming in at $0.60. Baxter International posted earnings of $0.57 per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 3.5%. The business is scheduled to report its next quarterly earnings results on Wednesday, February 7th.

On average, analysts expect that Baxter International will report full-year earnings of $2.42 per share for the current financial year, with EPS estimates ranging from $2.38 to $2.45. For the next year, analysts anticipate that the company will report earnings of $2.70 per share, with EPS estimates ranging from $2.62 to $2.85. Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Baxter International.

Baxter International (NYSE:BAX) last announced its quarterly earnings data on Wednesday, October 25th. The medical instruments supplier reported $0.64 EPS for the quarter, beating the Zacks’ consensus estimate of $0.59 by $0.05. The business had revenue of $2.71 billion during the quarter, compared to analyst estimates of $2.66 billion. Baxter International had a net margin of 9.88% and a return on equity of 15.00%. The firm’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.56 earnings per share.

BAX has been the topic of a number of analyst reports. Morgan Stanley reissued an “underweight” rating and issued a $55.00 target price (up previously from $52.00) on shares of Baxter International in a research note on Tuesday, July 25th. Cantor Fitzgerald set a $70.00 target price on shares of Baxter International and gave the company a “buy” rating in a research note on Wednesday, July 26th. Barclays PLC upped their target price on shares of Baxter International from $64.00 to $70.00 and gave the company an “overweight” rating in a research note on Thursday, July 27th. Cowen and Company reissued a “market perform” rating and issued a $68.00 target price (up previously from $66.00) on shares of Baxter International in a research note on Thursday, July 27th. Finally, Leerink Swann reissued an “outperform” rating and issued a $75.00 target price (up previously from $67.00) on shares of Baxter International in a research note on Thursday, July 27th. Six analysts have rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $67.00.

Shares of Baxter International (BAX) traded down $1.11 on Wednesday, hitting $63.88. 4,852,524 shares of the stock were exchanged, compared to its average volume of 2,684,560. The firm has a market capitalization of $35,530.00, a price-to-earnings ratio of 26.64, a P/E/G ratio of 2.16 and a beta of 0.68. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.80 and a quick ratio of 2.22. Baxter International has a 1-year low of $43.13 and a 1-year high of $65.70.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, January 2nd. Shareholders of record on Friday, December 1st will be paid a dividend of $0.16 per share. The ex-dividend date of this dividend is Thursday, November 30th. This represents a $0.64 annualized dividend and a yield of 1.00%. Baxter International’s dividend payout ratio is 34.59%.

In other Baxter International news, Director Thomas T. Stallkamp sold 8,920 shares of the company’s stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $62.28, for a total transaction of $555,537.60. Following the sale, the director now directly owns 16,263 shares of the company’s stock, valued at $1,012,859.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Carole J. Shapazian sold 4,020 shares of the company’s stock in a transaction dated Thursday, August 24th. The stock was sold at an average price of $61.61, for a total transaction of $247,672.20. Following the sale, the director now directly owns 13,868 shares in the company, valued at $854,407.48. The disclosure for this sale can be found here. Insiders have sold 5,022,380 shares of company stock worth $322,536,224 over the last ninety days. Insiders own 0.05% of the company’s stock.

A number of institutional investors have recently modified their holdings of BAX. Renaissance Technologies LLC grew its stake in shares of Baxter International by 2,859.6% during the first quarter. Renaissance Technologies LLC now owns 1,897,115 shares of the medical instruments supplier’s stock valued at $98,384,000 after purchasing an additional 1,833,015 shares during the last quarter. BlackRock Inc. grew its stake in shares of Baxter International by 1,941.1% during the first quarter. BlackRock Inc. now owns 46,937,709 shares of the medical instruments supplier’s stock valued at $2,434,190,000 after purchasing an additional 44,638,052 shares during the last quarter. United Capital Financial Advisers LLC grew its stake in shares of Baxter International by 1.3% during the first quarter. United Capital Financial Advisers LLC now owns 33,375 shares of the medical instruments supplier’s stock valued at $1,731,000 after purchasing an additional 441 shares during the last quarter. Schwab Charles Investment Management Inc. grew its stake in shares of Baxter International by 3.7% during the first quarter. Schwab Charles Investment Management Inc. now owns 1,593,978 shares of the medical instruments supplier’s stock valued at $82,664,000 after purchasing an additional 56,170 shares during the last quarter. Finally, HighVista Strategies LLC grew its stake in shares of Baxter International by 53.5% during the first quarter. HighVista Strategies LLC now owns 40,187 shares of the medical instruments supplier’s stock valued at $2,084,000 after purchasing an additional 14,000 shares during the last quarter. 82.85% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: This article was originally published by Watch List News and is owned by of Watch List News. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.watchlistnews.com/0-59-eps-expected-for-baxter-international-inc-bax-this-quarter/1712043.html.

About Baxter International

Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.

Get a free copy of the Zacks research report on Baxter International (BAX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.